Home > Insider Trading > Latest 13D and 13G Filings > 13G Filing (0001104659-25-028297)

Filing Details

Accession Number:: 0001104659-25-028297
Form Type:: 13G Filing
Publication Date:: 2025-03-25 20:00:00

Filed By:: Qatar Investment Authority
Company:: Lomond Therapeutics Holdings Inc.
Filing Date:: 2025-03-26
SEC Url:: 13G Filing

Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name	Beneficially Owned Number of Shares	Beneficially Owned Number of Aggregate Shares	Percent of Class
Qatar Investment Authority	0	2,500,000	7.76%

Filing

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Lomond Therapeutics Holdings, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

54173L101

(CUSIP Number)

03/24/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

54173L101

Names of Reporting Persons

Qatar Investment Authority

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

QATAR

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,500,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,500,000.00
8	Shared Dispositive Power 0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

2,500,000.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

7.76 %

Type of Reporting Person (See Instructions)

Comment for Type of Reporting Person: The numbers in rows 5, 7 and 9 represent 2,500,000 shares of common stock, par value $0.0001 ("Common Stock"), of Lomond Therapeutics Holdings, Inc. (the "Issuer") held of record by Q Healthcare Holding LLC, the Reporting Person's wholly-owned subsidiary (the "Subsidiary"). The percentage of class in row 11 is based on (i) 29,698,214 shares of Common Stock outstanding as of March 4, 2025 as reported in the Issuer's amended registration statement on Form S-1 filed with the Securities and Exchange Commission on March 10, 2025 and (ii) the 2,500,000 shares of Common Stock issued to the Subsidiary on March 24, 2025.

SCHEDULE 13G

Item 1.

(a)

Name of issuer:

Lomond Therapeutics Holdings, Inc.

(b)

Address of issuer's principal executive offices:

8 The Green, Suite 8490, Dover, Delaware, 19901

Item 2.

(a)

Name of person filing:

Qatar Investment Authority (the "Reporting Person")

(b)

Address or principal business office or, if none, residence:

Ooredoo Tower (Building 14), Al Dafna Street (Street 801), Al Dafna (Zone 61), Doha, State of Qatar

(c)

Citizenship:

Qatar

(d)

Title of class of securities:

Common Stock

(e)

CUSIP No.:

54173L101

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4.

Ownership

(a)

Amount beneficially owned:

2,500,000

(b)

Percent of class:

7.76%

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

2,500,000

(ii) Shared power to vote or to direct the vote:

(iii) Sole power to dispose or to direct the disposition of:

2,500,000

(iv) Shared power to dispose or to direct the disposition of:

Item 5.

Ownership of 5 Percent or Less of a Class.

Item 6.

Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

See Exhibit A.

Item 8.

Identification and Classification of Members of the Group.

Not Applicable

Item 9.

Notice of Dissolution of Group.

Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Qatar Investment Authority

Signature:	/s/ Andrew Watkins
Name/Title:	Andrew Watkins**/Associate General Counsel, Head of Compliance
Date:	03/26/2025

Comments accompanying signature: **Evidence of authority to sign on behalf of Qatar Investment Authority is set forth in a Certificate of Incumbency, dated February 2, 2022, and included as Exhibit B hereto.

Exhibit Information

Exhibit A - Item 7 Information Exhibit B - Certificate of Incumbency